Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.31 |
| ▸ | HTT | P42858 | 4/20 | 0.31 |
| ▸ | RAB9A | P51151 | 4/20 | 0.31 |
| ▸ | LMNA | P02545 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4611856 | 0.97 | ALDH1A1 (0.32) | ALDH1A1SMN1; SMN2HTTRAB9ALMNA | |
| SCHEMBL14039826 | 0.85 | HTT (0.46) | SMN1; SMN2HTTRAB9ALMNAMEN1 | |
| Hydrochloric Acid SCHEMBL4612119 | 0.85 | HTT (0.37) | SMN1; SMN2HTTRAB9ALMNAMEN1 | |
| SCHEMBL19762859 | 0.83 | — | — | |
| Bromide SCHEMBL4170067 | 0.83 | HTT (0.40) | SMN1; SMN2HTTRAB9ALMNAMEN1 | |
| Bromide SCHEMBL4169087 | 0.83 | HTT (0.50) | SMN1; SMN2HTTRAB9ALMNAMEN1 | |
| Hydrochloric Acid SCHEMBL5990146 | 0.81 | CYP3A4 (0.43) | LMNAMEN1KMT2A | |
| Bromide SCHEMBL22034658 | 0.81 | LMNA (0.43) | SMN1; SMN2HTTRAB9ALMNAMEN1 | |
| SCHEMBL10756971 | 0.79 | DNM1 (0.37) | SMN1; SMN2HTTRAB9ALMNAMEN1 | |
| SCHEMBL5172778 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090149668-A1 | Method for Producing Sodium Chloride-Free Ammonium Nitriles | CLARIANT INTERNATIONAL, LTD. (CH) | 2009-06-11 | — | — | US | disclosed |
| EP-1856033-B1 | IMPROVED METHOD FOR PRODUCING BI-FUNCTIONAL AMMONIUM NITRILES | CLARIANT PRODUKTE DEUTSCHLAND (DE) | 2008-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149668-A1 | Method for Producing Sodium Chloride-Free Ammonium Nitriles | CBR3, CBR1, AKR1C3 | ALDH1A1 653/4885SMN1; SMN2 3631/4885HTT 2436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.